Morgan Stanley Maintains Equal-Weight on Doximity, Lowers Price Target to $58
Morgan Stanley maintains Doximity (NYSE:DOCS) with a Equal-Weight and lowers the price target from $72 to $58.
58 Biggest Movers From Yesterday
Gainers
Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price target from Jefferies.
JP Morgan Downgrades Doximity to Underweight, Lowers Price Target to $60
JP Morgan analyst Jackson Ader downgrades Doximity (NYSE:DOCS) from Neutral to Underweight and lowers the price target from $70 to $60.
Cramer Gives His Opinion On GlaxoSmithKline, Asana And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Penn National Gaming, Inc. (NASDAQ: PENN) has been crushed, but selling the stock right now is a mistake.
Where Doximity Stands With Analysts
Within the last quarter, Doximity (NYSE:DOCS) has observed the following analyst ratings:
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc.
Expert Ratings For Doximity
Analysts have provided the following ratings for Doximity (NYSE:DOCS) within the last quarter:
Raymond James Maintains Outperform on Doximity, Raises Price Target to $80
Raymond James analyst Brian Peterson maintains Doximity (NYSE:DOCS) with a Outperform and raises the price target from $62 to $80.